Dr. Leprán István közleményjegyzéke
Közlemények impakt faktora:
Citációk (független) száma:
I. Közlemények
1.Kane K.A., Leprán I., McDonald F.M., Parratt J.R., Szekeres L.
The effects of prolonged oral adminstration of a new antidysrhythmic drug (Org 6001) on coronary artery ligation dysrhythmias in conscious and anesthetized rats.
J. Cardiovasc. Pharmacol. 2: 411-423, 1980.IF (1980) = 2.047
Citációk:(10)
Vink J.: Biomed. Mass. Spectrom. 7: 592, 1980.
Marshall R.J.: Gen. Pharmacol. 12: 315, 1981.
Marshall R.J.: Br. J. Pharmacol. 74: 381, 1981.
Mertz T.E.: J. Pharmacol. Exp. Ther. 223: 580, 1982.
Au T.L.S.: Br. J. Pharmacol. 79: 929, 1983.
Winslow E.: Pharmacol. Ther. 24: 401, 1984.
Dai S.: Arch. Int.Physiol. Bio. 95: 195, 1987.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Brooks R.R.: Eur. J. Pharmacol. 164: 521, 1989.
Paroczai M.: Pharmacol. Res. 22: 463, 1990.
2.Leprán I., Nemecz Gy., Koltai M., Szekeres L.
Effect of a linoleic acid-rich diet on the acute phase of coronary occlusion in conscious rats: influence of indomethacin and aspirin.
J. Cardiovasc. Pharmacol. 3: 847-853, 1981.IF (1981) = 1.978
Citációk:(49)
Charnock J.S.: Comp. Bioc. Biop. 75: 47, 1983.
Manning A.S.: J. Mol. Cell. Cardiol. 16: 497, 1984.
Meerson F.Z.: Va. Med. Nank. 47, 1984.
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Charnock J.S.: Ann. Qutr. M. 29: 83, 1985.
Charnock J.S.: Ann. Quitr. M. 29: 306, 1985.
Codde J.P.: Clin. Sci. 69: 691, 1985.
McLennan P.L.: Can. J. Phys. 63: 1411, 1985.
Hartog J.M.: Bas. Res. Cardiol. 81: 567, 1986.
Hoffmann P.: Prost. Leuk. M. 21: 113, 1986.
Petrova T.V.: Kosm. B. Av.M. 22: 6, 1986.
Shimkovi. M.V.: B. Exp. B. Med. 101: 582, 1986.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Lamers J.M.J.: Bas. Res. Cardiol. 82: 209, 1987.
McLennan P.L.: J. Cardiol. Pharmacol. 10: 293, 1987.
McLennan P.L.: Prost. Leuk. M. 27: 183, 1987.
Parratt JR, J. Mol. Cell. Cardiol. 19: 55. 1987.
Crandal D.L.: Prostagl. Leukotr. Med. 33: 115, 1988.
Grynberg A.: J. Mol. Cell. Cardiol. 20: 863, 1988.
McLennan P.L.: Am. Heart J. 116: 709, 1988.
Abraham R.: Am. J. Cardiol. 63: 269, 1989.
Hetzel B.S.: J. Clin. Epid. 42: 885, 1989.
McLennan P.L.: Lancet 2: 1451, 1989.
Meerson F.Z.: Biomed. Bioc. 48: S83, 1989.
Meerson F.Z.: J. Mol. Cell. Cardiol. 21: 299, 1989.
Oliver M.F.: Lancet 1: 1241, 1989.
Simkhovi B.Z.: Farmakol. Tox. 52: 24, 1989.
Adam O.: Kin. Woch. 68: 16, 1990.
Hock C.E.: A. J. Phys. 259: 1518, 1990.
McLennan P.L.: Am. J. Clin. 51: 53, 1990.
Sargent C.A.: Bioch. Soc. T. 18: 1077, 1990.
Matera M.G.: Curr. Ther. Res. 50: 511, 1991.
Naidina V.P.: Kosm. B. A. V. 25: 33, 1991.
McLennan P.L.: Am. J. Clin. Nutr. 58: 666, 1993.
Isensee H.: Arz. Forsch. 43: 94, 1993.
Rietz B.: Mol. Cell. Biochem. 119: 143, 1993.
Charnock J.S.: Nutrition 10: 161, 1994.
Charnock J.S.: Prog. Lip. Res. 33: 355, 1994.
Chemla D.: J. Mol. Cell. Cardiol. 27: 1747, 1995.
Christensen J.H.: Nutr. Res. 15: 1, 1995.
Chan P.: Pharmacol. 51: 118, 1995.
Chan P.: Life Sci. 59: 2067, 1996.
Chan P.: Life Sci. 61: 1999, 1997.
Hornstra G.: Br. J. Nutr. 80: S113, 1998.
Hornstra G.: FETT Lipid 101: 456 1999.
Charnock J.S.: Prost. Leuk. Ess. 61: 243, 1999.
Charnock J.S.: Prost. Leuk. Ess. 62: 129, 2000.
McLennan P.L.: Lipids 36.Suppl.S.: S111, 2001.
Demaison L.: Cell. Mol. Life Sci. 59: 463, 2002.
3.Leprán I., Koltai M., Szekeres L.
Effect of non-steroid anti-inflammatory drugs in experimental myocardial infarction in rats.
Eur. J. Pharmacol. 69: 235-238, 1981. IF (1981) = 3.372
Citációk:(28)
Au T.L.S.: Brit. J. Pharmacol. 79: 929, 1983.
Johnston K.M.: Brit. J. Pharmacol. 78: 29, 1983.
Johnston K.M.: Can. J. Physiol. Pharm. 61: 1340, 1983.
Such L.: J. Pharmacol. 14: 283, 1983.
Wenzel D.G.: Pharmacol. Res. 15: 167, 1983.
Nikolov R.: Meth. Find. E.: 5: 719, 1983.
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Huang T.F.: Arch. I. Pharmacol. 278: 128, 1985.
Hartog J.M.: Basic Res. Cardiol. 81: 141, 1986.
Northove B.J.: Brit. J. Pharmacol. 88: 141, 1986.
Nemecz G, J. Mol. Cell. Cardiol. 18: 739. 1986.
Shimkovi M.V.: Bull. Eksp. Biol. Med. 101: 582. 1986.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Eller B.T.: Pharmacol. 34: 121, 1987.
Lamers J.M.J.: Basic Res. Cardiol. 82: 209. 1987.
McLennan P.L.: J. Cardiovasc. Pharmacol. 10: 293, 1987.
McLennan P.L.: Prostagl. Leukotr. Med. 27: 183, 1987.
Parratt J.R.: J. Mol. Cell. Cardiol. 19: 55, 1987.
Blomberg S.: Act. Ae. Sci. 32: 173, 1988.
Hearse D.J.: J. Cardiol. Pharmacol. 11: 701, 1988.
Samveya V.M.: Kardiol. 28: 88, 1988.
Janero D.R.: Bioch. Pharmacol. 38: 4381, 1989.
Blomberg S.: Act. Anaes. Sci. 34: 1, 1990.
Hashimoto H.: Arzneimittel-Forsch. 40: 126, 1990.
Wainwright C.L.: Cardiol. Res. 25: 93, 1991.
Sulpice T.: J. Mol. Cell. Cardiol. 26: 831, 1994.
Iliodromitis E.K.: Cardiovasc. Drugs Therapy 13: 223, 1999.
4.Leprán I., Koltai M., Szekeres L.
Effect of cyclophosphamide on the acute phase of experimental myocardial infarction in rats.
Acta Physiol. Acad. Sci. Hung. 58: 311-315, 1981. IF (1981) = 0.378
Citációk: -
5.Fagbemi O., Leprán I., Parratt J.R., Szekeres L.
Naloxone inhibits early arrhythmias resulting from acute coronary ligation.
Brit. J. Pharmacol. 76: 504-506, 1982.IF (1982) = 4.540
Citációk:(57)
Bergey J.L.: Eur. J. Pharmacol. 90: 427, 1983.
Hernande J.: J. Pharmacol. Meth. 14: 560, 1983.
Lee A.Y. S.: P. Soc. Exp. M. 179: 219, 1985.
Wong T.M.: Clin. Exp. Pharmacol. 12: 379, 1985.
Zhan Z.Y.: Clin. Exp. Pharmacol. 12: 373, 1985.
Brasch H.: Brit. J. Pharmacol. 88: 733, 1986.
Dai S.: Agent & Action 17: 460, 19686.
Dai S.: Agent & Action 19: 26, 1986.
Huang X.D.: Brit. J. Pharmacol. 87: 475, 1986.
Lee A.Y.S.: Clin. Exp. Pharmacol. 13: 55, 1986.
Lee A.Y.S.: Clin. Exp. Pharmacol. 13: 707, 1986.
Chan M.Y.: Brit. J. Pharmacol. 90: 537, 1987.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Dai S.: Arch. Int. Pharmacol. 95: 195, 1987.
Helgesen K.G.: Pharmacol. 35: 121, 1987.
Lee A.Y.S.: Arch. Int. Pharmacol. 286: 212, 1987.
Lee A.Y.S.: Neurosci. 80: 289, 1987.
Wong T.M.: Neurosci. 77: 61, 1987.
Kow W.W.: Agent & Action 24: 95, 1988.
Kow W.W.: Brit. J. Pharmacol. 93: 723, 1988.
Kow. W.W.: Clin. Exp. Pharmacol. 15.: 23, 1988.
Kow W.W.: Clin. Exp. Pharmacol. 15: 733, 1988.
Sarne Y.: Life Sci. 43: 859, 1988.
Boachiea G.: Brit. J. Pharmacol. 97: 801, 1989.
Cerbai E.: Eur. J. Pharmacol. 162: 491, 1989.
Saini V.: Cardiovasc. Res. 23: 1001, 1989.
Sitsaper R.: Brit. J. Pharmacol. 97: 795, 1989.
Lee A.Y.S.: Int. J. Cardiol. 27: 145, 1990.
Thornhil J.: Can. J. Phys. 68: 392, 1990.
Kaschube M.: Cardiol. Res. 25: 230, 1991.
Markiewicz K.: Clin. Cardiol. 14: 813, 1991.
Sarne Y.: Brit. J. Pharmacol. 102: 696, 1991.
Lee A.Y.S.: Brit. J. Pharmacol. 107: 1057, 1992.
Chang A.C.C.: Agents Actions 35: 212, 1992.
Maslov L.N.: Bulletin of Exp. Biol. and Med. 112: 1066, 1991.
Lee A.Y.S.: Cardiovasc. Res. 26: 392, 1992.
Pugsley M.K.: Eur. J. Pharmacol. 212: 15, 1992.
Kan M.N.: Proc. Soc. Exp. Biol. Med. 200: 518, 1992.
Curtis M.J.: Cardiovasc. Res. 27: 703, 1993.
Levin G.: Gen. Pharmacol. 24: 423, 1993.
Maslov L.N.: Bull. Exp. Biol. Med. 116: 966, 1993.
Maslov L.N.: Int. J. Cardiol. 40: 89, 1993.
Oldroyd K.G.: Cardiovasc. Res. 27: 296, 1993.
Pugsley M.K.: Cardiovasc. Drug Res. 11: 151, 1993.
Wu J.P.: Eur. Heart J. 14: 1273, 1993.
Oldroyd K.G.: Br. J. Clin. Pharmacol. 37: 289, 1994.
He B.: Acta Pharmacol. Sin. 16: 169, 1995.
Mcintosh M.A.: J. Pharm. Pharmacol. 47: 52, 1995.
Maslov L.N.: Clin. Exp. Pharmacol. Physiol. 22: 812, 1995.
Bian JS, J.Mol.Cell.Cardiol. 30: 2103-2110. 1998.
Buratti T, Cardiology 90: 43, 1998.
Hung C.F.: Life Sci. 63: 1205, 1988.
Murphy D.B.: J. Cardiovasc. Pharmacol. 33: 122, 1999.
Buratti T.: Cardiology 90: 43, 1998.
Gervais H.W.: Resuscitation 34: 255, 1997.
Lishmanov Y.B.: Kardiologiya 42: 51, 2002.
Pugsley M.K.: Pharmacol. Ther. 93: 51, 2002.
6.Koltai M., Leprán I., Nemecz Gy., Szekeres L.
Experimental myocardial infarction in adjunant arthritic rats.
J. Cardiovasc. Pharmacol. 4: 363-369, 1982. IF(1982) = 2.638
Citációk:(5)
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Curtis M.J.: Brit. J. Pharmacol. 86: 663, 1985.
Dirosa M.: Agents Actions 17: 284, 1986.
Vadas P.: Lab. Invest. 55: 391, 1986.
Hirschel R.: Exp. Pathol. 31: 175, 1987.
7.Leprán I., Koltai M., Szekeres L.
Effect of actinomycin D and cycloheximide on experimental myocardial infarction in rats.
Eur. J. Pharmacol. 77: 197-199, 1982.IF (1982) = 3.469
Citációk:(5)
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Curtis M.J.: Brit. J. Pharmacol. 86: 663, 1985.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Strohm C.: Cardiovasc. Res. 55: 602, 2002.
8.Fagbemi O., Kane K.A., Leprán I., Parratt J.R., Szekeres L.
Antiarrhythmic actions of meptazinol, a partial agonist at opiate receptors, in acute myocardial ischaemia.
Brit. J. Pharmacol. 79: 455-460, 1983. IF (1983) = 4.959
Citációk:(25)
X: Lancet 2: 384, 1983.
Rabkin S.W.: Res. Comm. S4: 339, 1983.
Creamer J.E.: Eur. Heart J. 6: 717, 1985.
Holmes B.: Drugs 30: 285, 1985.
Blair J.R.: Anaesthesiol. 65: A406, 1986.
Rabkin S.W.: Eur. J. Pharmacol. 130: 47, 1986.
Addicks K.: Brit. J. Pharmacol. 90: 247, 1987.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Rabkin S.W.: Arch. Int. Pharmacol. 289: 267, 1987.
Rabkin S.W.: Clin. Exp. Pharmacol. 15: 565, 1988.
Blair J.R.: Anaesthesiol. 71: 565, 1989.
Boachiea G.: Brit. J. Pharmacol. 97: 801, 1989.
Cerbai E.: Eur. J. Pharmacol. 162: 491, 1989.
Sitsapes R.: Brit. J. Pharmacol. 97: 795, 1989.
Helgesen K.G.: Pharm. Tox. 66: 217, 1990.
Lee A.: Int. J. Cardiol. 27: 145, 1990.
Maslov L.N.: Bull. Exp. Biol. Med. 112: 1066, 1991.
Lishmanov Y.B.: Vestn. Ross. Akad. Med. Nauk 11-12: 47, 1992.
Maslov L.N.: Vopr. Med. Khim. 38: 21, 1992.
Alarcon S.: J. Pharm. Pharmacol. 44: 275, 1992.
Curtis M.J.: Cardiovasc. Res. 27: 703, 1993.
Pugsley M.K.: Cardiovasc. Drug Rev. 11: 151, 1993.
Pugsley M.K.: Eur. J. Pharmacol. 261: 303, 1994.
Maslov L.N.: Clin. Exp. Pharmacol. Physiol. 22: 812, 1995.
Pugsley M.K.: Pharmacol. Therapeut. 93: 51, 2002.
Wang C.D.: Invertebr. Reprod. Dev. 44: 89, 2003.
9.Fazekas T., Leprán I., Selmeczi A., Udvary É., Szekeres L.
Chloroquin (Delagil) hatása heveny szívizom ischaemiában.
Kísérl. Orvostud. 35: 483-490, 1983. IF (1983) = 0
Citációk: -
10.Koltai M., Leprán I., Nemecz Gy., Szekeres L.
The possible mechanism of protection induced by dexamethasone against sudden death due to coronary ligation in conscious rats.
Brit. J. Pharmacol. 79: 327-329, 1983. IF (1983) = 4.959
Citációk:(10)
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Dirosa M.: Agents Actions 17: 284, 1986.
Vadas P.: Lab. I.N.V. 55: 391, 1986.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Hirata F.: Neuroc. Path. 7: 33, 1987.
Dux E.: Neurosci. 34: 203, 1990.
Peers S.H.: Am. R. Resp. D. 141: S18, 1990.
Duval D.: Prostagl. Leukotr. Essent. Fatty Acids 45: 85, 1992.
Sautebin L.: Pharmacol. Res. 25: 1, 1992.
Cheung P.H.: J. Pharmacol. Toxicol. Meth. 29: 179, 1993.
11.Leprán I., Koltai M., Siegmund W., Szekeres L.
Coronary artery ligation, early arrhythmias, and determination of the ischemic area in conscious rats.
J. Pharmacol. Meth. 9: 219-230, 1983. IF (1983) = 1.071
Citációk:(55)
Meerson F.Z.: Kardiol. 25: 29, 1985.
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Meerson F.Z.: Kardiol. 26: 19, 1986.
Uematsu T.: J. Pharmacol. Met. 16: 53, 1986.
Varró A.: J. Pharmacy Pharmacol. 38: 772, 1986.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Hoffmann P.: Arch. Toxicol. 61: 79, 1987.
Meerson F.Z.: Bas. Res. Cardiol. 82: 123, 1987.
Meerson F.Z.: Clin. Cardiol. 10: 783, 1987.
Meerson F.Z.: Dan SSSR. 293: 489, 1987.
Meerson F.Z.: Kardiol. 27: 85, 1987.
Meerson F.Z.: Kardiol. 27: 87, 1987.
Meerson F.Z.: Va. Med. Nauk. 47: 1987.
Varró A.: Drug Exp. Cl. 13: 21, 1987.
Varró A.: J. Pharm. Pharmacol. 39: 483, 1987.
Kinoshita K.: Jpn. Circ. 52: 1384, 1988.
Meerson F.Z.: Fiziol. Zh. 34: 71, 1988.
Meerson F.Z.: B. Exp. B. Med. 105: 780, 1988.
Reichal R.: Eur. J. Pharmacol. 157.: 75, 1988.
Dzhanpol E.G.: B. Exp. B. Med. 107.: 501, 1989.
Himori N.: Am. J. Phys. 256.: 1719, 1989.
Hoffmann P.: Arch. Exp. Ve. 43: 515, 1989.
Meerson F.Z.: Kardiol. 29: 88, 1989.
Ballagi-Pordány G.: Diabet. Res. C. 8: 109, 1990.
Hoffmann P.: Biomed. Biochem. 49: 121, 1990.
Meerson F.Z.: Kardiol. 30: 67, 1990.
Meerson F.Z.: Kosm. B.A.V. 24: 28, 1990.
Rousseau S.: Bas. Res. Cardiol. 85: 404, 1990.
Schoemak R.G.: Bas. Res. Cardiol. 85: 9, 1990.
Schoemak R.G.: Bas. Res. Cardiol. 85: 404, 1990.
Schoemak R.G.: Eur. J. Pharmacol. 182: 527, 1990.
Kojima M.: Bas. Res. Cardiol. 86: 179, 1991.
Meslov L.N.: B. Exp. B. Med. 111: 18, 1991.
Occhinto F.: Phytother. R. 5: 9, 1991.
Schoemak R.G.: J. Cardiovasc. Pharmacol. 17: 949, 1991.
Schoemak R.G.: J. Mol. Cell. Cardiol. 23: 187, 1991.
Wascher T.C.: Arzneimittel Forsch. 41: 119, 1991.
Belichard P.: Bas. Res. Cardiol. 87: 433, 1992.
Melissenvranchen H.J.M.G.: J. Cardiovasc. Pharmacol. 19: 163, 1992.
Ohoi I.: Folia Pharmacol. Jap. 100: 87, 1992.
Lishmanov Y.B.: Vestnik Ross. Akad. Med. Nauk. 3: 5, 1992.
Hoffman P.: J. Pharm. Pharmacol. 45: 1093, 1993.
Belleminbaurreau J.: Eur. J. Pharmacol. 256: 115, 1994.
Belleminbaurreau J.: J. Pharmacol. Tox. Meth. 31: 31, 1994.
Pahor H.: J. Am. Ger. Soc. 42: 50, 1994.
Zimmermann T.: Arzneimittel Forsch. 44: 474, 1994.
Kalkman E.A.J.: J. Mol. Cell. Cardiol. 27: 2483, 1995.
Ravingerova T.: J. Mol. Cell. Cardiol. 27: 1937, 1995.
Verscheure Y.: J. Cardiovasc. Pharmacol. 25: 126, 1995.
Melissenvrancken H.J.A.P.: Circulation 93: 349, 1996.
Chen J.M.: Microvasc. Res. 54: 214, 1997.
Chen J.M.: Jpn. J. Physiol. 49: 499, 1999.
Nossuli T.O.: Am J. Physiol. 278: H1049, 2000.
Leenen F.H.H.: Hypertension 37: 209, 2001.
Kompa A.R.: J. Pharmacol. Toxicol. 43: 199, 2000.
12.Fazekas T., Csáti S., Leprán I., Udvary É., Szekeres L.
Hyperlipaemiás krízis hatása az ischaemiás-kutyaszív működésére (in Hungarian) - (Effect of hyperlipaemic crisis on the functioning of the ischaemic dog heart)
Kísérl. Orvostud. 36: 10-15, 1984. IF (1984) = 0
Citációk: -
13.Lefer A.M., Burke S.E., Leprán I.
Preservation of ischemic myocardial tissue with an antagonist of vasoconstrictor eicosanoids.
Can. J. Physiol. Pharmacol. 62: 1487-1491, 1984.IF (1984) = 0.887
Citációk:(14)
Brezinski M.E.: Am. Heart J. 110: 1161, 1985.
Hands D.: J. Hetero. Ch. 23: 1333, 1986.
Hock C.E.: Eur. J. Pharmacol. 122: 213, 1986.
Hock C.E.: Res. Comm. Cp. 52: 285, 1986.
Brezinski M.E.: J. Cardiol. Pharmacol. 9: 65, 1987.
Brezinski M.E.: Meth. Find. E. 9: 703, 1987.
Stahl G.L.: Blood Vess. 24: 24, 1987.
Smith E.F.: J. Cardiol. Pharmacol. 13: 715, 1989.
Tsao P.S.: Res. Comm. Chem. Pathol. Pharm. 70: 205, 1990.
Fiedler V.B.: Pharmacotherapy 11: 77, 1991.
Taneyama C.: Cardiovasc. Drug Rev. 8: 339, 1990.
Evangelou A.M.: Prost. Leuk. Ess. Fatty Acids 50: 1, 1994.
Protiva M.: J. Heterocyclic Chem. 33: 497, 1996.
Singh U.: Prostagland. Leukotr. Ess. Fatty Acids 56: 105, 1997.
14.Lefer A.M., Leprán I., Roth D.M., Smith J.B.
Specificity of anti-leukotriene actions of nicardipine.
Pharmacol. Res. Comm. 16: 1141-1150, 1984.IF (1984) = 0.834
Citációk:(9)
Dellosa D.: Pharmacol. Res. 18: 1043, 1986.
Sirois P.: Prostaglandin 31: 1117, 1986.
Frishman W.H.: Curr. Pharmacol. Cardiol. 12: 285, 1987.
Levitt H.M.A.: Meth. Find. E.: 9: 269, 1987.
Sorkin E.M.: Drugs 33: 296, 1987.
Yanagisa A.: Bas. Res. Cardiol. 82: 186, 1987.
Frishmann W.H.: Med. Clin. Na. 72: 449, 1988.
Schranz D.: Int. Cardiol. M. 14: 595, 1988.
Falcone R.C.: J. Pharmacol. Exp. Ther. 262: 1095, 1992.
15.Bullock G.R., Leprán I., Parratt J.R., Szekeres L., Wainwright C.L.
Effect of a combination of metoprolol and dazmegrel on myocardial infarct size in rats.
Brit. J. Pharmacol. 86: 235-240, 1985.IF (1985) = 4.093
Citációk:(5)
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Grover G.J.: J. Cardiovasc. Pharmacol. 11: 29, 1988.
Karasawa A.: J. Pharmacol. 11: 722, 1988.
Pieper G.M.: Prost.Leuk. Ess. 33: 13, 1988.
Grover G.J.: Circ. Res. 64: 575, 1989.
16.Darius H., Lefer A.M., Leprán I., Smith J.B.
In vivo interaction of prostacyclin with an inhibitor of cyclic nucleotide phosphodiesterase, HL 725.
Brit. J. Pharmacol. 84: 735-741, 1985. IF (1985) = 4.093
Citációk:(5)
Gresele P.: Thromb. Res. 55: 12, 1986.
Kitzen J.M.: Life Sci. 48: Pl.31, 1991.
Martinez G.R.: J. Med. Chem. 35: 620, 1992.
Spiecker M.: Thromb. Res. 70: 405, 1993.
Buerke M.: Thromb. Res. 88: 89, 1997.
17.Koltai M., Tósaki Á., Leprán I., Szekeres L.
Glucocorticoids in myocardial and cerebral infarction.
Agents Actions 17: 278-283, 1985. IF (1985) = 1.091
Citációk:(2)
Hirata F.: Neuroc. Path. R. 7: 33, 1987.
Hall R.: Can. J. Anaesth. 37: 762, 1990.
18.Leprán I., Lefer A.M.
Protective actions of propyl gallate, a lipoxygenase inhibitor, of the ischemic myocardium.
Circ. Shock. 15: 79-88, 1985. IF (1985) = 2.189
Citációk:(20)
Slapke J.: Biomed. Bioch. 45: 1267, 1986.
Chatelai P.: Circ. 75: 1083, 1987.
Hahn R.A.: Jpn. Pharmacol. Exp. 242: 62, 1987.
Deturco E.B.R.: J. Clin. Inv. 81: 700, 1988.
Toki Y.: Prostaglandins 35: 555, 1988.
Cohen M.V.: Ann. Int. Med. 111: 918, 1989.
Cornell R.P.: Am. J. Phys. 257: R839, 1989.
Gower J.D.: Bioch. Pharmacol. 38: 213, 1989.
Ito T.: Jpn. Circ. J. 53: 1115, 1989.
Janero D.R.: Bioch. Pharmacol. 38: 4381, 1989.
Schror K.: Biomed. Bioc. 48: 729, 1989.
Young J.S.: Ciric. Shock 32: 243, 1990.
Hahn R.A.: J. Pharmacol. Exp. Ther. 256: 94, 1991.
Yu J.S.: Biorganic & Med. Chem. Lett. 2: 1121, 1992.
Nihro Y.: J. Med. Chem. 35: 1618, 1992.
Hock C.E.: Cardiovasc. Res. 26: 1206, 1992.
Wu T.W.: Biochem. Pharmacol. 48: 419, 1994.
Allen S.: Circulation 97: 2406, 1998.
Sciuto A.M.: J. Appl. Toxicol. 21: 33, 2001.
Back M.: Acta Physiol. Scand. 174.Suppl.: 648, 2002
19.Leprán I., Parratt J.R., Szekeres L., Wainwright C.L.
The effects of metoprolol and dazmegrel, alone and in combination, on arrhythmias induced by coronary artery occlusion in conscious rats.
Brit. J. Pharmacol. 86: 229-234, 1985. IF (1985) = 4.093
Citációk:(8)
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Curtis M.J.: J. Mol. Cell. Cardiol. 19: 399, 1987.
Cross P.E.: Ann. Rep. H. 22: 95, 1987.
Dai S.: Arch. Int. Phys. 95: 195, 1987.
Dai S.: Arch. Int. Phys. 97: 341, 1989.
Salinas P.: Eur. J. Pharmacol. 209: 105, 1991.
Shaw L.A.: Brit. J. Pharmacol. 117: 817, 1996.
Iskit A.B.: Pharmacol. Res. 33: 13, 1996.
20.Leprán I., Lefer A.M.
Ischaemia aggravating effects of platelet-activating factor in acute ischemia.
Basic Res. Cardiol. 80: 135-141, 1985.IF (1985) = 0.926
Citációk:(63)
Botting J.H.: Mol. Asp. Med. 8: 307, 1985.
Hock C.E.: Eur. J. Pharmacol. 122: 213, 1986.
Lucchesi B.R.: Ann. Rev. Pharmacol. 26: 201, 1986.
Spinnewy B.: Prostaglandin. 34: 337, 1987.
Stahl G.L.: Blood Vess. 24: 24, 1987.
Stahl G.L.: Circ. Shock. 23: 165, 1987.
Armstead W.M.: Circ. Res. 62: 1, 1988.
Domingo M.T.: Bioc. Biochim. 151: 730, 1988.
Fiedler V.B.: Pharmacothe. Rev. 8: 158, 1988.
Janero D.R.: J. Pharmacol. Met. 20: 237, 1988.
Janero D.R.: Thromb. Res. 50: 789, 1988.
Stahl G.L.: J. Pharmacol. Exp. 244: 898, 1988.
Fukuzawa K.: Lipids 24: 236, 1989.
Joseph R.: Stroke 20: 609, 1989.
Koltai M.: Cardiol. Drug Rev. 7: 177, 1989.
Koltai M.: Eur. J. Pharmacol. 164: 293, 1989.
Nidorf S.M.: Card. Res. 23: 273, 1989.
Qian C.G.: J. Lipid. M. 1: 113, 1989.
Yeo Y.K.: Bioc. Biop. A. 1001: 25, 1989.
Westlin W.: Circulation 80: 1828, 1989.
Berti F.: J. Cardiol. Pharmacol.16: 727, 1990.
Chernov Y.N.: Farmakol. Tox. 53: 64, 1990.
Janero D.R.: Res. Comm. Cardiol. 67: 201, 1990.
Lindsber P.J.: J. Lipid. Med. 3: 2141, 1990.
Maruyama M.: A. Heart. J. 120: 510, 1990.
Mest H.J.: Pharmacol. Res. 22: 445, 1990.
Montruc G.: A. J. Path. 137: 71, 1990.
Deavers S.I.: J. Lipid. M. 4: 145, 1991.
Leong L.: J. Lipid. M. 4: 277, 1991.
Berti E.: Adv. Prost. 21: 939, 1991.
Chakrabarty S.: Eur. Heart J. 12: 583, 1991.
Massey C.V.: J. Clin. Int. 88: 2106, 1991.
Berti F.: Thromb. Res. 65: 13, 1992.
Graham-R.M.: Clin. Sci. 82: 535, 1992.
Kroegel C.: Drugs & Agin. 2: 345, 1992.
Leong L.L.L.: Cardiovasc. Res. 26: 126, 1992.
Leong L.L.L.: J. Mol. Cell. Cardiol. 24: 641, 1992.
Ma X.L.: J. Pharmacol. Exp. Ther. 260: 1229, 1992.
Schwinder R.H.G.: Am. Heart. J. 124: 320, 1992.
Stephens C.J.: Cardiovasc. Res. 26: 25, 1992.
Chopra K.: Meth. Find. Exp. Clin. Pharmacol. 15: 437, 1993.
Katoh S.: Cardiovasc. Res.: 27: 1430, 1993.
Ranaut K.: Meth. Find. Exp. Biol. Med. 15: 9, 1993.
Wang K.S.: Surgery 113: 76, 1993.
Evangelou A.M.: Prost. Leuk. Ess. Fatty Acids 50: 1, 1994.
Graham R.M.: J. Lip. Med. Cell. Sign. 9: 167, 1994.
Gupta J.B.: Angiol. 45: 25, 1994.
Ioculano M.: J. Cardiovasc. Pharmacol. 23: 7, 1994.
Jones K.P.: Thromb. Res. 75: 503, 1994.
Evangelou A.: Biol. Trance Elem. Res. 50: 43, 1995.
Goudevenos J.: Eur. Heart J. 16: 1036, 1995.
Reddy D.S.: Meth. Find. Exp. Clin. Pharmacol. 17: 383, 1995.
Prasad K.: J. Mol. Cell. Cardiol. 28: 375, 1996.
Feuerstein G.: J. Lipid Mediators Cell Signalling 15: 255, 1997.
Palmer J.S.: J. Urol. 158: 1186, 1997.
Auchampach J.A.: Basic Res. Cardiol. 93: 361, 1998.
Tselepis A.D.: Cardiovasc. Res. 43: 183, 1999.
Elisaf M.: Platelets 10: 124, 1999.
Peplow P.V.: Prostagl. Leukotr. Ess. 61: 65, 1999.
Montrucchio G.: Physiol. Rev. 80: 1669, 2000.
Iwazaki S.: Hepato.-Gastroenterol. 48: 197, 2001.
Goudevenos J.: Eur. J. Clin. Invest. 31: 15, 2001.
Ford D.A.: Prog. Lipid. Res. 41: 6, 2002.
21.Tósaki Á., Koltai M., Joó F., Ádám G., Szerdahelyi P., Leprán I., Takáts I., Szekeres L.
Actinomycin D suppresses the protective effect of dexamethasone in rats effected by global cerebral ischaemia.
Stroke 16: 501-505, 1985.IF (1985) = 3.323
Citációk:(27)
Rosenblu W.I.: Lab. I.N.V. 55: 252, 1986.
Sztriha L.: Neurosci. 17: 107, 1986.
Criscnol G.R.: J. Neurosurg. 69: 254, 1988.
Zilylan Y.Z.: J. Neurochem. 51: 1338, 1988.
Ziylan Y.Z.: J. Neurochem. 52: 684, 1989.
Dux E.: Neurosci. 34: 203, 1990.
Ziylan Y.Z.: J. Neurochem 53: 203, 1990.
Johanssen F.F.: Acta Neurol. Scand. 84: 1, 1991.
Abraham C.: Prog. Brain Res. 91: 23, 1992.
Szabo M.E.: Free Rad. Biol. 13: 609, 1992.
Szabo M.E.: Exp. Eye Res. 55: 39, 1992.
Criscuolo G.R.: Yale J. Biol. Med. 66: 277, 1993.
Droylefaix M.T.: Int. J. Tiss. React.-Exp. Clin. Asp. 15: 85, 1993.
Jorgensen M.B.: Acta Neurol. Scand. 87: 9143, 1993.
Szabo M.E.: Ophthalmic Res. 25: 1, 1993.
Tuor U.I.: Brain Res. 604: 165, 1993.
Tuor U.I.: Stroke 24: 452, 1993.
Anderson D.K.: Brain Res. 637: 119, 1994.I
Decourtenmyers G.M.: Stroke 25: 487, 1994.
Miller D.B.: J. Pharmacol. Exp. Ther. 270: 752, 1994.
Wang Y.L.: Acta Pharmacol. Sin. 15: 201, 1994.
Kim J.S.: J. Neurol. Sci. 128: 28, 1995.
Szabo M.E.: Ophthalmic Res. 27: 102, 1995.
Murakami K.: Stroke 28: 1797, 1997.
Koistinaho J.: Stroke 30: 1900, 1999.
Samdani A.F.: Neurosurg. Quart. 9: 120, 1999.
Norris J.W.: Stroke 35: 228, 2004.
22.Koltai M., Leprán I., Szekeres L., Viossat I., Chabrier E., Braquet P.
Effect of BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs.
Eur. J. Pharmacol. 130: 133-136, 1986. IF (1986) = 3.325
Citációk:(30)
Mest H.J.: Biomed. Bioc. 46: S534, 1987.
Riedel A.: Pharmacol. Res. 19: 703, 1987.
Terashita Z.J.: J. Pharmacol. Exp. 243: 378, 1987.
Vargaftig B.B.: Br. Med. B. 43: 312, 1987.
Armstead W.M.: Circ. Res. 62: 1, 1988.
Mest H.J.: Biomed. Bioc. 47: S219, 1988.
Yaakob H.B.: Brit. J. Pharmacol. 95: P521, 1988.
Wainwright C.L.: Biomed. Bioc. 47: S224, 1988.
Mándi Y.: Immunology 67: 370, 1989.
Stanton A.W.B.: Brit. J. Pharmacol. 97: 643, 1989.
Wainwright C.L.: Eur. Heart J. 10: 235, 1989.
Demizot Y.: Agents Actions 29: 167, 1990.
Felix S.B.: Bas. Res. Cardiol. 85: 217, 1990.
Felix S.B.: J. Cardiovasc. Pharmacol. 15: 989, 1990.
Felix S.B.: J. Lipid Med. 2: 9, 1990.
Mest H.J.: Pharmacol. Res. 22: 445, 1990.
Mest H.J. Pol. J. Pharmacol. 42: 283, 1990.
Felix S.B.: Res. Exp. Med. 191: 1, 1991.
Lindahl M.: Exp. Lung. Res. 17: 77, 1991.
Rabinovici R.: Lipids 26: 1257, 1991.
Vleeming W.: J. Cardiovasc. Pharmacol. 20: 790, 1992.
Aepfelbacher M.: J. Immunol. 148: 2186, 1992.
Mest H.J.: Pharmacol. Res. 25: 173, 1992.
Ramosfranco J.: Circ. Res. 72: 786, 1993.
Evangelou A.M.: Prost. Leuk. Ess. Fatty Acids 50: 1, 1994.
Desquand S.: Ther. 48: 585, 1993.
Muller H.W.: Circ. Res. 77: 54, 1995.
Feuerstein G.: J. Lipid Med. Cell Signall. 15: 255, 1997.
Loucks E.B.: J. Invest. Surg. 10: 321, 1997.
Montrucchio G.: Physiol. Rev. 80: 1669, 2000.
Tibirica E.: Cardiovasc. Drug Rev. 19: 313, 2001.
23.László F.A., Leprán I., Baláspiri L.
Cardiovascular effects of vesopressin agonists and antagonist in rats.
Exp. Clin. Endocrinol. (Life Sci. Adv.) 7: 237-241, 1988.IF (1988) = 0.341
Citációk:(1)
Serradeillegal C.: Fund. Clin. Pharmacol. 9: 17, 1995.
24.Leprán I., Szekeres L., Kékes Szabó A.
Dietary influence of different vegetable oils on the incidence of ischemia and reperfusion induced arrhythmias in anaesthetized rats.
Pharmacol. Res. 20: 81-82, 1988.IF (1988) = 0.577
Citációk: -
25.Fazekas T., Leprán I., Udvary É., Szekeres L.
Nicotinic acid-induced myocardial ischaemia due to 'coronary steal' phenomenon.
Eur. J. Pharmacol. 183: 322-323, 1990.IF (1990) = 3.621
Citációk: -
26.Leprán I., Szekeres L.
Effect of dietary sunflower seed oil on the severity of reperfusion-induced arrhythmias in anesthetized rats.
J. Cardiovasc. Pharmacol. 19: 40-44, 1992.IF (1992) = 1.498
Citációk:(7)
Lai L.J.: Thromb. Res. 76: 281, 1994.
Chan P.: Pharmacol. 51: 118, 1995.
Knezl V.: Life Sci. 65: 1931, 1999.
Charnock J.S.: Prost. Leuk. Ess. 62: 129, 2000.
McLennan P.L.: Lipids 36.Suppl.S: S111, 2001.
Gyonos I.: Cardiovasc. Drug Ther. 15: 233, 2001.
Demaison N.: Cell. Mol. Life Sci. 59: 463, 2002.
27.Leprán I., Papp J.Gy.
Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion.
J. Cardiovasc. Pharmacol. 24 Suppl. 1: S9-S15, 1994.IF (1994) = 1.680
Citációk:(14)
Olivier J.P.: J. Cardiovasc. Pharmacol. 24: S39, 1994.
van Zwieten P.A.: J. Hypertens. 15: 117, 1997.
Morris S.T.W.: J. Hum. Hypertens. 11: 629, 1997.
Prichard B.N.C.: J. Hum. Hypertens. 11.Suppl.1: S29, 1997.
Feldman J, J. Auton. Nervous Syst. 72: 94-97. 1998.
Prichard B.N.C.: J. Hypertens. 17: S41, 1999.
Takechi S.J.: J. Cardiovasc. Pharmacol. 33: 409, 1999.
Wolk R.: Eur. J. Pharmacol. 367: 25, 1999.
Bousquet P.: Drugs 58: 799, 1999.
Wolk R.: Int. J. Cardiol. 74: 89, 2000.
Poisson D.: J. Pharmacol. Exp. Ther. 293: 929, 2000.
Bousquet P.: J. Cardiovasc. Pharmacol. 35Suppl.4.: S21-S25, 2000.
Bousquet P.: Am. J. Hypertens. 14Part2/Suppl.S: S317, 2001.
Khirmanov V.N.: Terapevt. Arkh. 75: 85, 2003.
28.Leprán I.
Könyvismertetés. Mezey G.- Mohamed Aslam: Gyógyszeres interakciók. (könyvbírálat)
Orvosi Hetilap 135: 1057-58, 1994.
Citációk: -
29.Leprán I., Baczkó I., Varró A., Papp J.Gy.
ATP-sensitive potassium channel modulators: both pinacidil and glibenclamide produce antiarrhythmic activity during acute myocardial infraction in conscious rats.
J. Pharmacol. Exp. Ther. 277: 1215-1220, 1996. IF (1996) = 3.432
Citációk:(15)
Link M.S.: Circulation 100: 413, 1999.
Ooie T.: J. Cardiol. Fail. 6: 250, 2000.
Coetzee W.A.: Eur. J. Pharmacol. 402: 263, 2000.
Svorc P.: Physiol. Res. 49: 711, 2000.
del Valle H.F.: Cardiovasc. Res. 50: 474, 2001.
Das B.: Naunyn-Sch. Arch. Pharmacol. 364: 383, 2001.
Das B.: Pharmacology 63: 134, 2001.
Negroni J.A.: Basic Res. Cardiol. 97: 55, 2002.
Billman G.E.: Drug Develop. Res. 55 Spec. Iss.: 59, 2002.
Yazar A.: Pharmacol. Res. 45: 183, 2002.
Posa I.: Arzneimittel-Forsch. 52: 552, 2002.
Das B.: Eur. J. Pharmacol.: 437: 165, 2002.
Das B.: Method Find. Exp. Clin. 25: 97, 2003.
Das B.: Pharmacol. Res. 47: 447, 2003.
Das B.: Pol. J. Pharmacol. 55: 771, 2003.
30.Baczkó I., Leprán I., Papp J.Gy.
Influence of anesthetics on the incidence of reperfusion-induced arrhythmias and sudden death in rats.
J. Cardiovasc. Pharmacol. 29: 196-201, 1997.IF (1997) = 1.537
Citációk: -
31.Baczkó I., Leprán I., Papp J.Gy.
KATP channel modulators increase survival rate during coronary occlusion-reperfusion in anaesthetized rats.
Eur. J. Pharmacol. 324: 77-83, 1997. IF (1997) = 1.96
Citációk:(22)
Kita H.: J. Cardiovasc. Pharmacol. 32: 791, 1998.
Links M.S.: Circulation 100: 413, 1999.
Wirth K.J.: J. Pharmacol. Exp. Ther. 291: 474, 1999.
Wirth K.J.: N-.S. Arch. Pharmacol. 360: 295, 1999.
Wirth K.J.: N.-S. Arch. Pharmacol. 361: 155, 2000.
Tang W.C.: Am. J. Physiol. 279: H1609, 2000.
del Valle H .F.: Cardiovasc. Res. 50: 474, 2001.
Das B.: Naunyn-Sch. Arch. Pharmacol. 364: 383, 2001.
Das B.: Pharmacology 63: 134, 2001.
Negroni J.A.: Basic Res. Cardiol. 97: 55, 2002.
Ravingerova T.: Physiol. Res. 51: 109, 2002.
Billman G.E.: Drug Develop. Res. 55Spec.Iss.: 59, 2002.
Tsai C.H.: J. Pharmacol. Exp. Ther. 301: 234, 2002.
Das B.: Eur. J. Pharmacol. 437: 165, 2002.
Das B.: Pharmacol. Res. 47: 447, 2003.
Das B.: Method Find. Exp. Clin. 25: 97, 2003.
Yu S.P.: Prog. Neurobiol. 70: 363, 2003.
Riveline J.P.: Diabetes Metab. 29: 207, 2003.
Csonka Cs.: J. Cardiovasc. Pharmacol. 41: 916, 2003.
Yahiro E.: Cardiology 99: 61, 2003.
Das B.: Pol. J. Pharmacol. 55: 771, 2003.
Lascano E.C.: Medicina-Buenos Aires 64: 30, 2004.
32.Farkas A., Leprán I., Papp J.Gy.
Comparison of the antiarrhythmic and the proarrhythmic effect of almokalant in anaesthetised rabbits.
Eur. J. Pharmacol. 346: 245-253, 1998.IF (1998) = 1.992
Citációk:(2)
Batey A.J.: Br. J. Pharmacol. 135: 1003, 2002.
Wickenden A.D.: Pharmacol. & Ther. 94: 157, 2002.
33.El-Reyani N.E., Bozdogan Ö., Leprán I., Baczkó I., Papp J.Gy.
Comparison of the efficacy of glibenclamide and glimepiride in reperfusion induced arrhythmias in rats.
Eur. J. Pharmacol. 365: 187-192, 1999.IF (1999) = 2.047
Citációk: (6)
Miyashita T.: Jpn. Circ. J. 64: 602, 2000.
Legtenberg R.J.: Eur. J. Pharmacol. 419: 85, 2001.
Billman G.E.: Drug Develop. Res. 55.Spec.Iss.: 59, 2002.
Lawrence C.L.: Br. J. Pharmacol. 136: 746, 2002.
Massi-Benedetti M.: Clin. Ther. 25: 799, 2003.
Csonka Cs.: J. Cardiovasc. Pharmacol. 41: 916, 2003.
34.Baczkó I., El-Reyani N.E., Farkas A., Virág L., Iost N., Leprán I., Mátyus P., Varró A., Papp J.Gy.
Antiarrhythmic and electrophysiological effects of GYKI-16638, a novel N-(phenoxyalkyl)-N-phenylalkylamine, in rabbits.
Eur J Pharmacol 404: 181-190, 2000.IF(2000) = 2.236
Citációk:(2)
Mátyus P.: Pharmazie 56: S50, 2001.
Beatch G.N.: Drug. Develop. Res. 55.Spec:Iss. 45, 2002.
35.Bozgogan Ö., Leprán I., Papp J.Gy.
Effect of the combination of glibenclamide, an ATP-dependent potassium-channel blocker, and Metoprolol, a cardioselective -adrenoceptor blocker, during myocardial infarction in conscious rats.
Turk. J. Med. Sci. 30: 517-522, 2000.IF(2000) = 0
Citációk: -
36.EI-Reyani N.E., Baczkó I., Leprán I., Papp J.Gy.
Effect of glibenclamide and glimepiride treatment on the development of myocardial infarction in rats.
Acta Physiol. Hung. 87: 173-184, 2000.IF(2000)= 0.270
Citációk: -
37.Pálfi Á., Siminka J.A:, Pataricza M., Tekulics P., Leprán I., Papp J.Gy., Gulya K.
Postischemic calmodulin gene expression in the rat hippocampus.
Life Sci. 68: 2373-2381, 2001.IF (2001) = 1.758
Citációk:(3)
Shimoda K.: Genet. Mol. Biol. 25: 43, 2002.
Sato T.: J. Pharmacol. Exp. Ther. 304: 1042, 2003.
Sato T.: Pharmacology 71: 38, 2004.
38.Farkas A., Leprán I., Papp J.Gy.
Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
J. Cardiovasc. Pharmacol. 39: 287-297, 2002.IF (2002) = 1.602
Citációk:(1)
Bányász T.: Curr. Med. Chem. 11: 45, 2004.
39.Leprán I., Papp J.Gy.
Effect of long-term oral pretreatment with levosimendan on cardiac arrhythmias during coronary artery occlusion in couscious rats.
Eur. J. Pharmacol. 464: 171-176, 2003.IF (2002) = 2.342
Citációk:(1)
Innes C.A.: Drugs 63: 2651, 2003.
II. Folyóiratban megjelent abstractok
1.Leprán I., Siegmund W., Szekeres L.
Method of acute coronary-occlusion in anesthetized closed chest rats.
Acta Physiol. Acad. Sci. Hung. 53: 190, 1979.IF (1979) = 0.378